Results 11 to 20 of about 825 (170)

A Case of Meige Syndrome in a Pediatric Patient With Schizophrenia [PDF]

Clinical Case Reports
Long‐term treatment with multiple antipsychotic medications for schizophrenia may increase the risk of developing tardive dystonia, including Meige syndrome.
Kosuke Mizobuchi, Hisashi Tanii, Koji Kanai   +2 more
doaj   +3 more sources

Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial [PDF]

Frontiers in Psychiatry
ObjectivesThis clinical trial primarily aimed to investigate the effects of blonanserin on social functioning in patients with first-episode schizophrenia.MethodsIn this prospective, multi-centre, single-arm clinical trial study, blonanserin (flexible ...
Tianqi Gao, Hong Deng, Jianhua Sheng, Bin Wu, Zhening Liu, Fude Yang, Lina Wang, Shaohua Hu, Xijin Wang, Haiyun Li, Chengcheng Pu, Xin Yu   +11 more
doaj   +4 more sources

Comparison of Efficacies of a Blonanserin Transdermal Patch and Blonanserin Oral Formulation for Psychiatric Symptoms in Patients With Schizophrenia Treated With Laxatives Using a Japanese Claims Database [PDF]

Neuropsychopharmacology Reports
Background Laxative use has recently been indicated as a risk factor for hospitalization in patients with schizophrenia. Oral antipsychotic therapy for patients with schizophrenia treated with laxatives may be problematic due to gastrointestinal ...
Ken Inada, Hiroyuki Muraoka, Yuji Matsumoto, Daisuke Fukui, Tomomi Watanabe, Yuriko Masuda, Sachie Inoue, Takahiro Masuda   +7 more
doaj   +3 more sources

A Simple and Sensitive HPLC-MS/MS Assay for the Quantitation of Blonanserin and N-Desethyl Blonanserin in Rat Plasma and Its Application to Pharmacokinetic Study

Journal of Analytical Methods in Chemistry, 2022
A high-performance liquid chromatographic method coupled with triple quadrupole mass spectrometry (LC-MS/MS) for the analysis of blonanserin and its active metabolite, N-desethyl blonanserin, in rat plasma has been developed and validated. The biological
Shan-qing Huang, Xiao-lin Li, Zhan-zhang Wang, Hao-yang Lu, Tao Xiao, Xiao-jia Ni, Shu-jing Liu, Ming Zhang, De-wei Shang, Yu-guan Wen   +9 more
doaj   +2 more sources

Blonanserin suppresses impulsive action in rats

Journal of Pharmacological Sciences, 2019
High impulsivity will increase the risk of criminal behavior, drug abuse, and suicide. We chose two drugs by following a strategy recently we proposed for identifying potential anti-impulsivity drugs, and examined the effects on impulsive action in rats ...
Naoya Nishitani, Hitomi Sasamori, Yu Ohmura, Takayuki Yoshida, Mitsuhiro Yoshioka   +4 more
doaj   +5 more sources

The Influence of Blonanserin Supersaturation in Liquid and Silica Stabilised Self-Nanoemulsifying Drug Delivery Systems on In Vitro Solubilisation

Pharmaceutics, 2023
Reformulating poorly water-soluble drugs as supersaturated lipid-based formulations achieves higher drug loading and potentially improves solubilisation and bioavailability.
Amalie Møller, Hayley B. Schultz, Tahlia R. Meola, Paul Joyce, Anette Müllertz, Clive A. Prestidge   +5 more
doaj   +2 more sources

Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances

Journal of Pharmacological Sciences, 2021
Schizophrenia significantly limits social functioning with positive and negative symptoms and cognitive dysfunction. Blonanserin (LONASEN®), a novel second-generation antipsychotic approved for treating schizophrenia in Japan in 2008, reportedly shows ...
Yoshifumi Inoue, Kimiko Tsuchimori, Hiroshi Nakamura   +2 more
doaj   +2 more sources

Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range [PDF]

Journal of Pharmacological Sciences, 2015
Antagonism of the dopamine D3 receptor has been hypothesized to be beneficial for schizophrenia cognitive deficits, negative symptoms and extrapyramidal symptoms.
Satoko Baba, Takeshi Enomoto, Tomoko Horisawa, Takashi Hashimoto, Michiko Ono   +4 more
doaj   +2 more sources

Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study

Neuropsychopharmacology Reports, 2020
Objective To report the efficacy and safety of blonanserin in patients with schizophrenia compared with risperidone in a Japanese multicenter, randomized, double‐blind study based on post hoc sensitivity analysis in addition to the previous results ...
Philip D. Harvey, Hiroshi Nakamura, Sadanori Miura   +2 more
doaj   +2 more sources

Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2014
BackgroundThe present study aimed to evaluate cardiometabolic risks [weight gain, blood lipid levels (total cholesterol and triglycerides), blood glucose levels, hemoglobin A1c (HbA1c) levels, and corrected QT interval (QTc) prolongation] associated with
Taro Kishi, Yuki Matsuda, Nakao Iwata
doaj   +2 more sources